FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2008
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

COHEN ALAN SEYMOUR
2. Issuer Name and Ticker or Trading Symbol

HEMAGEN DIAGNOSTICS INC [ HMGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

54 WINSTON ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

5/20/2008
(Street)

NEWTOWN, MA 02459
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                  256626   I   By trusts  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options   $.35   5/20/2008        5000   (1)      5/20/2008   5/20/2018   Common Stock   5000   $0   5000   D    
Stock Options   $.35   5/20/2008        5000   (2)      5/20/2008   5/20/2018   Common Stock   5000   $0   5000   D    
Stock Options   $.35   5/20/2008        10000   (2)      5/20/2008   5/20/2018   Common Stock   10000   $0   10000   D    
Stock Options   $.25   5/20/2008        5000   (3)      5/20/2008   5/20/2018   Common Stock   5000   $0   5000   D    
Stock Options   $.14   5/20/2008        5000   (4)      5/20/2008   5/20/2018   Common Stock   5000   $0   5000   D    

Explanation of Responses:
( 1)  Granted pursuant to 2007 Stock Incentive Plan for awards owed for service as a director for the fiscal year ending September 30, 2004; exercise price reflects closing price as of March 18, 2005, the date reporting person was otherwise entitled to receive the award.
( 2)  Granted pursuant to 2007 Stock Incentive Plan for awards owed for service as a director for the fiscal year ending September 30, 2005; exercise price reflects closing price as of March 3, 2006, the date reporting person was otherwise entitled to receive the award.
( 3)  Granted pursuant to 2007 Stock Incentive Plan for awards owed for service as a director for the fiscal year ending September 30, 2006; exercise price reflects closing price as of April 24, 2007, the date reporting person was otherwise entitled to receive the award.
( 4)  Granted pursuant to 2007 Stock Incentive Plan for awards owed for service as a director for the fiscal year ending September 30, 2007.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
COHEN ALAN SEYMOUR
54 WINSTON ROAD
NEWTOWN, MA 02459
X



Signatures
/s/William P. Hales as Attorney-in-Fact for Alan S. Cohen 5/21/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Hemagen Diagnostics (CE) (USOTC:HMGN)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Hemagen Diagnostics (CE)
Hemagen Diagnostics (CE) (USOTC:HMGN)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Hemagen Diagnostics (CE)